Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

The pharmacogenomics journal - 1 Nov 2016

Nieuweboer A J M, Smid M, de Graan A-J M, Elbouazzaoui S, de Bruijn P, Eskens F A L M, Hamberg P, Martens J W M, Sparreboom A, de Wit R, van Schaik R H N, Mathijssen R H J

Abstract excerpt

Docetaxel is used for treatment of several solid malignancies. In this study, we aimed for predicting docetaxel clearance and docetaxel-induced neutropenia by developing several genetic models. Therefore, pharmacokinetic data and absolute neutrophil counts (ANCs) of 213 docetaxel-treated cancer patients were collected. Next, patients were genotyped for 1936 single nucleotide polymorphisms (SNPs) in 225 genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Metabolic Clearance Rate
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inactivation, Metabolic

Share to Membrane Transport Proteins

Share to Neutropenia

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Taxoids

Source

Identifiers

PMID: 26345519
DOI: 10.1038/tpj.2015.66

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.PMID 26345519Read ↗

Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.Semantic proximity Read ↗

Predicting paclitaxel-induced neutropenia using the DMET platform.Semantic proximity Read ↗

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.Semantic proximity Read ↗

An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel.Semantic proximity Read ↗

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).Semantic proximity Read ↗

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Semantic proximity Read ↗

Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohortSemantic proximity Read ↗

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.